Skip to main content
Fig. 7 | Arthritis Research & Therapy

Fig. 7

From: Tumor necrosis factor alpha neutralization attenuates immune checkpoint inhibitor-induced activation of intermediate monocytes in synovial fluid mononuclear cells from patients with inflammatory arthritis

Fig. 7

The main findings. Pembrolizumab inhibits the engagement of PD-1 with PD-L1. Removing this immunological brake in SFMC cultures resulted in differentiation of monocytes into intermediate monocytes. The intermediate monocytes showed an increased production of CCL-2 (MCP-1) and TNFα upon pembrolizumab stimulation. No increase was seen in IL-6 production. Inhibiting TNFα production with adalimumab decreased pembrolizumab-induced MCP-1 production. Blocking IL-6 secretion with tocilizumab did not decrease the pembrolizumab-induced immune reactions. Illustration made with BioRendor

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us